{"id":"NCT00567255","sponsor":"Orexigen Therapeutics, Inc","briefTitle":"A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects","officialTitle":"A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2009-06","completion":"2009-06","firstPosted":"2007-12-04","resultsPosted":"2014-11-21","lastUpdate":"2014-11-21"},"enrollment":1496,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Obesity","Overweight"],"interventions":[{"type":"DRUG","name":"Naltrexone SR 32 mg/bupropion SR 360 mg/day","otherNames":["NB32"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"BEHAVIORAL","name":"Ancillary therapy","otherNames":[]}],"arms":[{"label":"NB32","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity.","primaryOutcome":{"measure":"Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28","timeFrame":"Baseline, 28 weeks","effectByArm":[{"arm":"NB32","deltaMin":-6.45,"sd":0.2},{"arm":"Placebo","deltaMin":-1.89,"sd":0.26}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":18,"exclusionCount":24},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["23408728"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":992},"commonTop":["Nausea","Constipation","Headache","Upper respiratory tract infection","Insomnia"]}}